Head and Neck Cancer Therapeutics: Global Markets

Abstract

Report Scope:
This report aims to provide a comprehensive study of the global market for head and neck cancer therapeutics, both in terms of quantitative and qualitative data, to help businesses develop growth strategies, assess the market landscape, analyze their positions in the current marketplace, and make informed business decisions regarding head and neck cancer therapeutic drugs.

An in-depth analysis of the global head and neck cancer therapeutics market includes historical data and market projections on sales by type of diagnostic method, treatment type, disease indication, route of administration, therapeutic class, and end user. It describes the different types of head and neck cancers (lip and oral cavity cancer, laryngeal cancer, oropharyngeal cancer, salivary gland cancer, nasopharyngeal cancer, and hypopharyngeal cancer) and their current and historical market revenues. This report also categorizes the global head and neck cancer therapeutics market based on the route of administration (injectable and oral).

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market shares. The report also discusses pipeline analysis and the new regulatory landscape of the drugs marketed.

Report Includes:
- 64 data tables and 17 additional tables
- A comprehensive overview of the global markets for head and neck cancer therapeutics within the industry
- Analyses of the global market trends, with historic market revenue data for 2020 and 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
- Estimation and forecast the actual market size for head and neck cancer therapeutics, and corresponding market share analysis by diagnostic method, treatment type, disease indication, route of administration, therapeutic class, end-user, and region
- Assessment of major driving factors, opportunities and challenges in this innovation driven market, with emphasis on COVID-19 impact on the head and neck cancer therapeutics market
- Discussion of the industry value chain analysis providing a systematic study of key intermediaries involved, with emphasis on new products development, regulatory scenario, and reimbursement and pricing factors
- In-depth information on increasing investments on R&D activities, key technology issues, industry specific challenges, and major types of end-user markets
- Market share analysis of the key market participants in the global pharmaceuticals industry, their research priorities, product portfolios, pipeline products, and company competitive landscape
- Descriptive company profiles of the leading global players, including AstraZeneca plc, Bristol-Myers Squibb, Eli Lilly and Co., Sanofi S.A., Merck & Co., and Pfizer Inc.

Content

Table of Contents
Chapter 1 Introduction
1.1 Study Goals and Objectives
1.2 Scope of Report
1.3 Methodology and Information Sources
1.4 Geographic Breakdown
1.5 Analyst's Credentials
1.6 BCC Custom Research
1.7 Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
3.1 Head and Neck Cancer Overview
3.2 Incidence
3.3 Stages of Head and Neck Cancer
3.4 Risk Factors
3.4.1 Alcohol and Tobacco Usage
3.4.2 Occupational Exposure
3.4.3 Radiation Exposure
3.4.4 Gender
3.4.5 Human Papillomavirus Infection (HPV)
3.5 Symptoms
3.6 Blockbuster Drugs
3.6.1 Erbitux (Cetuximab)
3.6.2 Taxotere (Docetaxel)
3.6.3 Keytruda (Pembrolizumab)
3.6.4 Opdivo (Nivolumab)
3.6.5 Hydrea (Hydroxyurea)
Chapter 4 Regulatory Structure
4.1 Regulatory Challenges for Selected Countries
4.1.1 United States
4.1.2 Canada
4.1.3 Europe
4.1.4 Japan
4.1.5 India
4.1.6 Brazil
Chapter 5 Market Breakdown, by Diagnostic Method
5.1 Diagnostic Methods
5.1.1 Biopsy
5.1.2 Imaging
5.1.3 Endoscopy
5.1.4 Other Diagnostic Methods
Chapter 6 Market Breakdown, by Treatment Type
6.1 Overview
6.2 Treatment Types
6.2.1 Surgery
6.2.2 Radiation Therapy
6.2.3 Chemotherapy
6.2.4 Immunotherapy
6.2.5 Targeted Therapy
Chapter 7 Market Breakdown, by Disease Indication
7.1 Overview
7.2 Disease Indications
7.2.1 Lip and Oral Cavity Cancer
7.2.2 Laryngeal Cancer
7.2.3 Oropharyngeal Cancer
7.2.4 Salivary Gland Cancer
7.2.5 Nasopharyngeal Cancer
7.2.6 Hypopharyngeal Cancer
Chapter 8 Market Breakdown, by Route of Administration
8.1 Overview
8.2 Route of Administration
8.2.1 Injectable
8.2.2 Oral
Chapter 9 Market Breakdown, by Therapeutic Class
9.1 Overview
9.2 Therapeutic Classes
9.2.1 PD Inhibitors
9.2.2 EGFR Inhibitors
9.2.3 Microtubule Inhibitors
Chapter 10 Market Breakdown, by End User
10.1 Overview
10.2 End Users
10.2.1 Hospitals
10.2.2 Specialty Clinics
10.2.3 Ambulatory Surgical Centers
10.2.4 Others
Chapter 11 Market Dynamics
11.1 Market Drivers
11.1.1 Immunotherapy against Autoimmune Disorders
11.1.2 Rising Incidence of Cancer Worldwide
11.1.3 Advances in Biochemistry and Genomics
11.1.4 High Unmet Need
11.2 Market Challenges
11.2.1 Lack of Oncology Professionals
11.2.2 High Cost of Biologic Therapies
Chapter 12 Impact of COVID-19 on the Market
12.1 Overview
12.2 Impact of COVID-19 on Head and Neck Cancer Therapeutics
12.2.1 Delay in Surgeries
12.3 Trade Restrictions and Supply Disruptions
Chapter 13 Pipeline Analysis
13.1 Overview
Chapter 14 Competitive Landscape
14.1 Overview
14.2 Global Company Ranking
Chapter 15 Company Profiles
ABBVIE INC.
ASTRAZENECA PLC
BAYER AG
BRISTOL-MYERS SQUIBB
ELI LILLY AND CO.
F. HOFFMANN-LA ROCHE LTD.
PFIZER INC.
MERCK & CO.
SANOFI-AVENTISList of Tables
Summary Table A : Global Market for Head and Neck Cancer Therapeutics, by Diagnostic Method, Through 2027
Summary Table B : Global Market for Head and Neck Cancer Therapeutics, by Disease Indication, Through 2027
Table 1 : New Cases of Head and Neck Cancer in Males and Females, by Cancer Type, 2020
Table 2 : Number of New Cases of Head and Neck Cancer, by Region, 2020
Table 3 : TNM Classification of Malignant Tumors of Head and Neck Cancer
Table 4 : Erbitux Drug of Head and Neck Cancer Therapeutics
Table 5 : Taxotere Drug of Head and Neck Cancer Therapeutics
Table 6 : Keytruda Disease Indication
Table 7 : Keytruda Drug of Head and Neck Cancer Therapeutics
Table 8 : Opdivo Drug of Head and Neck Cancer Therapeutics
Table 9 : Hydrea Drug of Head and Neck Cancer Therapeutics
Table 10 : Global Market for Head and Neck Cancer Therapeutics, by Diagnostic Method, Through 2027
Table 11 : Global Market for Biopsy Head and Neck Cancer Therapeutics, by Region, Through 2027
Table 12 : Global Market Shares of Biopsy Head and Neck Cancer Therapeutics, by Region, 2021
Table 13 : Global Market for Imaging Head and Neck Cancer Therapeutics, by Region, Through 2027
Table 14 : Global Market Shares of Imaging Head and Neck Cancer Therapeutics, by Region, 2021
Table 15 : Global Market for Endoscopy Head and Neck Cancer Therapeutics, by Region, Through 2027
Table 16 : Global Market Shares of Endoscopy Head and Neck Cancer Therapeutics, by Region, 2021
Table 17 : Global Market for Other Diagnostic Method Head and Neck Cancer Therapeutics, by Region, Through 2027
Table 18 : Global Market Shares of Other Diagnostic Method Head and Neck Cancer Therapeutics, by Region, 2021
Table 19 : Global Market for Head and Neck Cancer Therapeutics, by Treatment Type, Through 2027
Table 20 : Global Market for Surgery Head and Neck Cancer Therapeutics, by Region, Through 2027
Table 21 : Global Market Shares of Surgery Head and Neck Cancer Therapeutics, by Region, 2021
Table 22 : Global Market for Radiation Therapy Head and Neck Cancer Therapeutics, by Region, Through 2027
Table 23 : Global Market Shares of Radiation Therapy Head and Neck Cancer Therapeutics, by Region, 2021
Table 24 : Global Market for Chemotherapy Head and Neck Cancer Therapeutics, by Region, Through 2027
Table 25 : Global Market Shares of Chemotherapy Head and Neck Cancer Therapeutics, by Region, 2021
Table 26 : Global Market for Immunotherapy Head and Neck Cancer Therapeutics, by Region, Through 2027
Table 27 : Global Market Shares of Immunotherapy Head and Neck Cancer Therapeutics, by Region, 2021
Table 28 : Global Market for Targeted Therapy Head and Neck Cancer Therapeutics, by Region, Through 2027
Table 29 : Global Market Shares of Targeted Therapy Head and Neck Cancer Therapeutics, by Region, 2021
Table 30 : Global Market for Head and Neck Cancer Therapeutics, by Disease Indication, Through 2027
Table 31 : Global Market for Lip and Oral Cavity Head and Neck Cancer Therapeutics, by Region, Through 2027
Table 32 : Global Market Shares of Lip and Oral Cavity Head and Neck Cancer Therapeutics, by Region, 2021
Table 33 : Global Market for Laryngeal Head and Neck Cancer Therapeutics, by Region, Through 2027
Table 34 : Global Market Shares of Laryngeal Head and Neck Cancer Therapeutics, by Region, 2021
Table 35 : Global Market for Oropharyngeal Head and Neck Cancer Therapeutics, by Region, Through 2027
Table 36 : Global Market Shares of Oropharyngeal Head and Neck Cancer Therapeutics, by Region, 2021
Table 37 : Global Market for Salivary Gland Head and Neck Cancer Therapeutics, by Region, Through 2027
Table 38 : Global Market Shares of Salivary Gland Head and Neck Cancer Therapeutics, by Region, 2021
Table 39 : Global Market for Nasopharyngeal Head and Neck Cancer Therapeutics, by Region, Through 2027
Table 40 : Global Market Shares of Nasopharyngeal Head and Neck Cancer Therapeutics, by Region, 2021
Table 41 : Global Market for Hypopharyngeal Head and Neck Cancer Therapeutics, by Region, Through 2027
Table 42 : Global Market Shares of Hypopharyngeal Head and Neck Cancer Therapeutics, by Region, 2021
Table 43 : Global Market for Head and Neck Cancer Therapeutics, by Route of Administration, Through 2027
Table 44 : Global Market for Injectable Head and Neck Cancer Therapeutics, by Region, Through 2027
Table 45 : Global Market Shares of Injectable Head and Neck Cancer Therapeutics, by Region, 2021
Table 46 : Global Market for Oral Head and Neck Cancer Therapeutics, by Region, Through 2027
Table 47 : Global Market Shares of Oral Head and Neck Cancer Therapeutics, by Region, 2021
Table 48 : Global Market for Head and Neck Cancer Therapeutics, by Therapeutic Class, Through 2027
Table 49 : Global Market for PD Inhibitors Head and Neck Cancer Therapeutics, by Region, Through 2027
Table 50 : Global Market Shares of PD Inhibitors Head and Neck Cancer Therapeutics, by Region, 2021
Table 51 : Global Market for EGFR Inhibitors Head and Neck Cancer Therapeutics, by Region, Through 2027
Table 52 : Global Market Shares of EGFR Inhibitors Head and Neck Cancer Therapeutics, by Region, 2021
Table 53 : Global Market for Microtubule Inhibitors Head and Neck Cancer Therapeutics, by Region, Through 2027
Table 54 : Global Market Shares of Microtubule Inhibitors Head and Neck Cancer Therapeutics, by Region, 2021
Table 55 : Global Market for Head and Neck Cancer Therapeutics, by End User, Through 2027
Table 56 : Global Market for Head and Neck Cancer Therapeutics in Hospitals, by Region, Through 2027
Table 57 : Global Market Shares of Hospital End Use in Head and Neck Cancer Therapeutics, by Region, 2021
Table 58 : Global Market for Specialty Clinic End Use in Head and Neck Cancer Therapeutics, by Region, Through 2027
Table 59 : Global Market Shares of Specialty Clinic End Use in Head and Neck Cancer Therapeutics, by Region, 2021
Table 60 : Global Market for Ambulatory Surgical Center End Use in Head and Neck Cancer Therapeutics, by Region, Through 2027
Table 61 : Global Market Shares of Ambulatory Surgical Center End Use in Head and Neck Cancer Therapeutics, by Region, 2021
Table 62 : Global Market for Other End Users of Head and Neck Cancer Therapeutics, by Region, Through 2027
Table 63 : Global Market Shares of Other End Users of Head and Neck Cancer Therapeutics, by Region, 2021
Table 64 : Head and Neck Cancer Therapeutics Drug Pipeline, Through 2021
Table 65 : Global Market Rankings and Company Revenue Share of Head and Neck Cancer Therapeutics, 2021
Table 66 : AbbVie Inc.: Annual Revenue, 2019–2021
Table 67 : AbbVie Inc.: Head and Neck Cancer Pipeline
Table 68 : AstraZeneca plc: Annual Revenue, 2019–2021
Table 69 : AstraZeneca plc: Head and Neck Cancer Pipeline
Table 70 : Bayer: Oncology Pharmaceutical Product Portfolio
Table 71 : Bristol-Myers Squibb: Head and Neck Cancer Drug Product Portfolio
Table 72 : Bristol-Myers Squibb: Head and Neck Cancer Drug Revenue, 2018–2020
Table 73 : Eli Lilly and Co.: Head and Neck Cancer Drug Product Portfolio
Table 74 : Eli Lilly and Co.: Head and Neck Cancer Drug Revenue, 2018–2020
Table 75 : Roche: Head and Neck Cancer Pipeline Product Portfolio
Table 76 : Pfizer's: Head & Neck Pipeline Product Portfolio
Table 77 : Merck & Co.'s: Head and Neck Cancer Drug Product Portfolio
Table 78 : Merck & Co.'s: Head and Neck Cancer Drug Revenue, 2018–2020
Table 79 : Sanofi-Aventis: Head and Neck Cancer Drug Product Portfolio